Business Wire

Leading Health Organizations Recommend the Use of Hand Dryers

30.6.2020 23:15:00 EEST | Business Wire | Press release

Share

The topic of hygiene has come to the forefront in mainstream media as reopening plans are introduced around the globe. While leading health organizations like the World Health Organization (WHO), and Centers for Disease Control and Prevention (CDC), recommend the use of hand dryers, misinformation about them remains online, and continues to be quoted and perpetuated. Leaders from Excel Dryer, manufacturer of XLERATOR® Hand Dryers, wish to deliver a message to educate the professionals, consultants and government officials who are creating reopening guidelines, and the general public, especially in times of COVID-19: Excel hand dryers are a safe, hygienic touchless solution and an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200630006010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Leading Health Organizations Recommend the Use of Hand Dryers (Graphic: Business Wire)

Kelly Reynolds, Ph.D., Professor and Department Chair at the Mel & Enid Zuckerman College of Public Health at the University of Arizona, offered an explanation as to the root of these misconceptions, stating that, “Consumers may only read [sensationalized] headlines which can influence public opinion toward biased or erroneous conclusions, [but] the fact is, the breadth of data available does not favor one hand drying method as being more hygienic or safer.”

Excel hand dryers provide a touchless hand drying solution to help prevent potential cross-contamination between restroom surfaces and wet hands. All dryers in Excel’s line are hygienic, but dryers with HEPA have been proven to add another level of protection. Viral efficiency testing conducted by the preeminent independent air media and filter testing company, LMS Technologies in April of 2020 found that XLERATOR®, XLERATOReco ® and XLERATORsync® Hand Dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream.

William Gagnon, vice president of marketing and sales at Excel Dryer, wishes to correct misinformation and biases about hand dryers. “Hand dryers are hygienic and have been used to properly dry hands for decades. In addition to top health organizations recommending their use, hand dryers also provide significant benefits over paper that are undisputable. For example, our recent test results prove XLERATOR hand dryers with HEPA Filtration Systems remove 99.999 percent of viruses from the airstream, something paper will never be able to do.”

Conversely, paper towels may not be as hygienic as the public believes. One independent study showed 17 species of bacteria on unused, recycled paper towels, including Bacillus, which can cause food poisoning. After their use, damp paper towels are a breeding ground for viruses and bacteria in and around trash receptacles and can be used to clog toilets and sinks creating a very unhygienic restroom environment. If the paper towels are out of stock, visitors cannot dry their hands at all, and wet hands have been shown to be 1,000 times more likely to transfer germs than dry hands.

Gagnon concluded, “I encourage members of the public and those individuals charged with the creation of guidelines, reopening plans or facilities operations, to dive deeper into news articles and hygiene studies rather than simply believing sensationalized, click-bait headlines born from biased results. Hand dryers are safe and hygienic. They dry hands completely, and are a top defense against the spread of germs.”

About Excel Dryer, Inc.

Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Twarog or Michelle Abdow
(Office) 413-787-1133
ltwarog@marketmentors.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye